September 08, 2023

2 min read


Hammami MB, et al. Abstract MPN-470. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 6-9, 2023; Houston.

The authors report no relevant financial disclosures.

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Study results presented at Society of Hematologic Oncology Annual Meeting highlight the potential effect that socio-racial characteristics may have on outcomes of patients with primary myelofibrosis.

Results also revealed a similar distribution of mutations among Black patients and patients of other races with primary myelofibrosis. This finding — consistent with prior reports — suggests genetic differences may not be the primary explanation for varying outcomes among patients of different racial backgrounds.

Graphic distinguishing meeting news

“There is a need to focus on addressing social disparities to ensure equitable access to high-quality care for all [patients with primary myelofibrosis],” M. Bakri Hammami, MD, of Jacobi Medical Center and Albert Einstein College of Medicine, said during a presentation. “Efforts to mitigate these disparities could encompass tailored treatment strategies, improved patient education and enhanced access to health care resources.”

Primary myelofibrosis — characterized by bone marrow fibrosis and clonal proliferation — is an aggressive subtype of BCR-ABL1-negative myeloproliferative neoplasms.

Prior research has consistently demonstrated poorer outcomes among racial or ethnic minority patients. However, the prognostic effect of socio-racial factors for patients with primary myelofibrosis has not been clearly established, according to study background.

Hammami and colleagues reviewed SEER data (2000 to 2020) to evaluate socio-racial characteristics and survival data for patients with primary myelofibrosis. They excluded cases with no histologic confirmation and those with no active follow-up (eg, autopsy or death certificate only).

The SEER review included 5,403 patients (median age, 69 years; range, 0-98; 60% men; 82% white; 8.4% Black; 9.6% other/unknown race).

Leading causes of death included primary myelofibrosis (37.1%), cardiac diseases (7%), pulmonary diseases (3.4%) and gastrointestinal diseases (1.2%).

Researchers estimated OS rates of 69% at 2 years and 42%.

Multivariate Cox regression analysis revealed several factors associated with poorer survival. These included older age, male sex (HR for men vs. women = 1.39; 95% CI, 1.27-1.53), Black race (HR for Black vs. non-Black = 1.2; 95% CI, 1.01-1.42) and earlier year of diagnosis. Income and marital status did not predict survival; married individuals exhibited reduced risk for all-cause mortality only.

Investigators then compared SEER findings with data from medical records of 51 patients (median age at diagnosis, 66 years; 57% men; 49% married) with primary myelofibrosis treated at their own institution. They reported the following breakdown by race: 35% white, 20% Black, 10% Asian and 35% other/unknown.

The Montefiore Medical Center database included genetic mutation data for 47 patients (Black, n = 10; non-Black, n = 37). Researchers reported the following genetic mutation distribution: JAK2 (70% for Black vs. 78% for non-Black), CALR (20% vs. 16%), MPL (0% vs. 3%), triple negative (10% vs. 3%), ASXL1 (40% vs. 5%), SRSF2 (20% vs. 8%) and TET2 (0% vs. 8%).

Researchers acknowledged study limitations, including its retrospective nature and the limited number of Black patients.